Accessibility Menu
Spectrum Pharmaceuticals logo

Spectrum Pharmaceuticals(NASDAQ) SPPI

This security has been delisted. This page is retained for historical reference.

Spectrum Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 1.032023-07-31
Spectrum Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 1.032023-07-24
1 month+7.29%USD 0.962023-06-30
3 month+0.98%USD 1.022023-05-02
Year to date+179.51%USD 0.372022-12-30
1 year+26.69%USD 0.812022-07-29
3 year-65.55%USD 2.992020-07-31
5 year-95.09%USD 20.972018-08-01
Since inception-99.24%USD 135.671996-09-26

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

SPPI Financials

Key Financial Metrics (TTM)

Gross Margin

82.28%

Operating Margin

-718.78%

Net Income Margin

-772.24%

Return on Equity

-207.06%

Return on Capital

-126.84%

Return on Assets

-75.58%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$22.87M

Operating Income

-$63.51M

EBITDA

-$65.46M

Operating Cash Flow

-$88.13M

Capital Expenditure

-$342.00K

Free Cash Flow

-$88.48M

Cash & ST Invst.

$56.14M

Total Debt

$28.84M

Spectrum Pharmaceuticals Performance Analysis

Spectrum Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 10,114,000N/A
Spectrum Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22022-06-30N/A
Q32022-09-30-100.0%
Q42022-12-31N/A
Q12023-03-3154.4%
Spectrum Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -1.02N/A
20222022-12-31USD -0.41-59.8%
Spectrum Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22022-06-30-87.4%
Q32022-09-3029.4%
Q42022-12-3159.3%
Q12023-03-3147.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2023YOY CHG

Revenue

$15.62M

N/A

Gross Profit

$14.55M

N/A

Gross Margin

93.19%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

86

N/A

Net Income

-$5.14M

+66.6%

EBITDA

-$4.06M

+73.4%

Quarterly Fundamentals

Name
Q1 2023YOY CHG

Total Cash

$56.14M

-37.1%

Total Debt

$28.84M

+2781.1%

Accounts Receivable

$33.64M

+5164.2%

Inventory

$12.86M

N/A

Long Term Debt

$28.84M

N/A

Short Term Debt

$771.00K

-23.0%

Return on Assets

-75.58%

N/A

Return on Invested Capital

-1.20%

N/A

Free Cash Flow

-$21.55M

+29.0%

Operating Cash Flow

-$21.44M

+29.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TCRTAlaunos Therapeutics, Inc.
$1.94+1.04%
CRGXCARGO Therapeutics, Inc. Common Stock
$4.47+0.00%
VACCVaccitech plc
$5.00+11.36%
THRXTheseus Pharmaceuticals, Inc.
$4.07+0.12%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
SOFISoFi Technologies
$16.46-0.01%
TAT&T
$24.13+0.05%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.